Background and objective: Target lobar volume reduction (TLVR) is an important efficacy outcome measure for bronchoscopic lung volume reduction (BLVR) treatment using one-way endobronchial valves (EBV) in patients with severe emphysema. The commonly used cut-off value for TLVR that expresses a perceivable clinical benefit is −350 mL. However, a scientifically determined minimal important difference (MID) for TLVR never has been published. The objective of the present study was to determine the MID for TLVR on HRCT in patients who were treated with EBV. Methods: A total of 318 patients with severe emphysema from two BLVR trials were analysed. Anchorbased methods were used to define the TLVR MID at 6 months follow-up. Forced expiratory volume in 1 s (FEV 1 ), residual volume (RV) and St. George's Respiratory Questionnaire (SGRQ) were used as anchors. Results: The calculated TLVR MID with each anchor was: FEV 1 −587 mL, RV −534 mL and SGRQ −560 mL. The combined MID (average of the three anchor-based MIDs) was −563 mL. Conclusion: Using the anchor-based method, we established a TLVR MID of −563 mL in patients with severe emphysema at 6 months follow-up after EBV treatment. This value can be useful for both interpreting the results from trials and clinical practice, as well as for designing future studies on lung volume reduction.
INTRODUCTION
Patients with severe emphysema do not respond well to the current regular treatment options. Bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBV) is a valid treatment option for patients with severe emphysema and proven absence of collateral ventilation. BLVR treatment using EBV shows high efficacy and an acceptable safety profile. [1] [2] [3] The purpose of EBV is to induce atelectasis in the most diseased lobe ('target lobe') ( Fig. 1) . Similarly in surgical lung volume reduction, this approach reduces hyperinflation, resulting in improved function of the diaphragm and chest wall mechanics and consequent relief of dyspnoea. 4, 5 The amount of target lobar volume reduction (TLVR) measured with HRCT is one of the most important outcome measures of BLVR treatment using EBV since it has been shown to be an important predictor for clinically meaningful changes after this treatment. 6 The currently accepted, but solely expert opinionbased, cut-off value for TLVR to reflect a meaningful clinical effect is a reduction of at least 350 mL 7 using quantitative HRCT analysis, this was established on the basis that in the 'VENT trial' the maximum TLVR in the control group receiving standard medical care rarely exceeded this level. 8 To our knowledge, an objectively calculated minimal important difference (MID) for TLVR never has been published. In this respect, the MID refers to the minimal TLVR that associates with significant improvements in clinically relevant outcomes of severe emphysema. 9 We have seen many patients with severe emphysema improving far more than the 350 mL cut-off value after BLVR treatment 1, 7, 10 and observed that the improvement might need to be more than the currently quoted 350 mL to be
SUMMARY AT A GLANCE
The minimal important difference (MID) for target lobar volume reduction after endobronchial valve treatment for emphysema is −563 mL. This MID can be useful for both interpreting the results from trials and clinical practice, as well as for designing future studies on lung volume reduction. appreciated by patients. Therefore, we hypothesized that the MID for TLVR is higher than the 350 mL threshold in patients with severe emphysema.
The objective of the present study was to determine the MID for TLVR in patients with severe emphysema who underwent BLVR treatment using EBV.
METHODS

Study design
We retrospectively analysed data from two large clinical trials investigating endobronchial valve treatment: The 'STELVIO trial' (Netherlands Trial Register number NTR2876 1 ) and the 'VENT trial' (NCT00129584 8 ). The STELVIO and VENT trial were approved by the ethics committees of all participating hospitals and all patients provided informed consent.
In total, 68 patients participated in the STELVIO trial and 321 patients participated in the VENT trial. Patients were included in our analyses when they both had an HRCT at baseline and 6 months follow-up after EBV treatment.
Measurements
Patients in both trials underwent HRCT scans at baseline and 6 months after the treatment. TLVR was calculated using quantitative HRCT analysis.
In the 'STELVIO trial' post hoc computerized quantifications using Thirona Lung Quantification (version 15.01) 11 were performed on the data set to determine the amount of TLVR (Fig. 2) . Spirometry and body plethysmography (MasterScreen; VIASYS, Höchberg, Germany) at baseline and 6 months follow-up were performed according to the American Thoracic Society/European Respiratory Society guidelines. 12 In the 'VENT trial', TLVR was measured by the study radiology core laboratory at the David Geffen School of Medicine (UCLA (University of California, Los Angeles)) through quantitative image analysis (MedQIA). Spirometry was performed based on the standardization of spirometry update by the American Thoracic Society 13 and body plethysmography was performed based on the American Association of Respiratory Care clinical practice guideline. 14 At baseline and at 6 months follow-up, patients in both trials were administered the full version of the St. George's Respiratory Questionnaire, a quality of life questionnaire with scores ranging from 0 to 100, with higher scores indicating worse quality of life. 15 
MID calculation
To determine the MID, an anchor-based approach was used. The anchor-based method uses external indicators whose clinical validity is established and with a demonstrated MID in the target population. 16 For the anchor-based method, we considered forced expiratory volume in 1 s (FEV 1 ) (MID 100 mL 
Data analysis
The absolute and relative changes from baseline to 6 months follow-up were calculated. For the anchorbased method, Pearson correlation coefficients were calculated. In line with our previous studies, we considered a Pearson correlation coefficient of r ≥ 0.4 to indicate a sufficiently strong association. 18, 20 Linear regression analyses were performed with change in TLVR as dependent variable and change in anchor score as independent variable. The MIDs of the anchors were then substituted into the equations derived from the linear regression analyses. Afterwards, the MID could be calculated from the established equation. P < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 22 (IBM, New York, NY, USA).
RESULTS
A total of 17 patients in the 'STELVIO trial' 1 and 54 patients in the 'VENT trial' 8 did not perform an HRCT scan at 6 months follow-up and consequently 318 patients could be included in the analyses. Reasons for not completing the 6 months follow-up were amongst others: ineligibility for treatment, patient decline for follow-up and EBV removal due to adverse events.
Patient characteristics at baseline and change in outcome parameters at 6 months follow-up are shown in Table 1 . The Pearson correlation coefficient of TLVR with 6MWD was 0.32. This correlation coefficient did not meet the commonly accepted 0.40 correlation coefficient threshold and could therefore not be included as anchor in the MID calculation. The correlation coefficients and the MID calculations of the anchors are shown in Table 2 .
Scatterplots of correlations of TLVR versus FEV 1 , RV and SGRQ at 6 months follow-up are shown in Figure 3 .
We calculated a TLVR MID of each anchor at 6 months follow-up: FEV 1 − 587 mL (relative MID −25.2%), RV −534 mL (relative MID −21.3%) and SGRQ −560 mL (relative MID −20.6%). Our combined MID (average of the three anchor-based MIDs) was −563 mL (relative −22.4%) at 6 months follow-up.
DISCUSSION
We have calculated for the first time a MID for TLVR in patients with severe emphysema. At 6 months followup after BLVR treatment using EBV the MID was -563 mL and the relative MID was −22.4%. Our findings differ significantly from the currently accepted, expert opinion-based, MID of 350 mL.
The MID that we established was approximately 50% higher than the currently accepted cut-off value for TLVR of −350 mL. Real data as basis for an MID for TLVR has never been published before and the cut-off value that is frequently used in the literature is based on expert opinion agreement. Based on our clinical experiences, we hypothesized that the MID should be above the currently accepted 350 mL threshold. 7, 10 A possible contribution to this discrepancy is that the previous estimate of the MID was probably based on pulmonary function testing outcomes, underestimating the size of lung volume reduction due to the redistribution of lung volume from the target to the ipsilateral and contralateral lobes, 21 leading to higher than necessary HRCT TLVR values, when compared to pulmonary function generated values.
All included patients underwent BLVR using EBV. The question arises whether MIDs based on anchor techniques can be used across different interventions as several processes may underlie the observed effects of interventions. 22 Possibly, MID determination in patients who undergo lung volume reduction surgery or other bronchoscopic treatment modalities such as lung volume reduction coils, airway sealants or thermal vapour ablation could provide different MID results. [23] [24] [25] [26] Further research is required to assess the influence of different bronchoscopic treatment options on the TLVR MID calculation.
In the present study, we focused on the volume reduction of the target lobe and did not take into consideration for example the ipsi-or contralateral lobes. The ipsi-and contralateral lobes could expand after treatment. It is also possible that the character of the remaining lobe is of importance, for example emphysematous residual lung may offset the degree of lobar collapse. This might be investigated in future research.
There are different methods for the calculation of MIDs, for example anchor-based methods that are patient-oriented and distribution-based methods which focus on distribution of outcomes. There is no consensus on the best methodology. One of the recommendations in the literature is that the MID should be based primarily on relevant patient-based and clinical anchors. 16 Therefore, we used the anchor-based method in the present study. For the anchor-based method, the choice of anchors can influence MID outcomes, it is important to carefully select these anchors. One of the requirements for a good anchor is a high enough association between the anchor and the outcome variable. 27 Despite the lower than 0.4 (0.38) Pearson correlation coefficient of the change in RV versus TLVR, the consistency of MID outcomes and our large sample size support the validity of our findings. Nextly, the anchor should be established in a comparable patient population. The anchors used in the present study, with exception of the FEV 1 anchor, were all established in patients who underwent BLVR to treat severe emphysema. Other studies determining MIDs included distribution-based methods as well. 28, 29 However, a study by Turner et al. stated that the lack of consistency across distribution-based measures suggests that these approaches should act only as temporary substitutes, pending availability of empirically established anchor-based MID values. 30 Terwee et al. even argue that distribution-based methods should not be used at all because they assess minimal detectable change, rather than minimal important change. 31 A limitation of the present study is that patients from two different BLVR trials were included. For example, the VENT trial 8 included patients with heterogeneous emphysema whereas the STELVIO trial 1 included patients with both heterogeneous and homogeneous emphysema and excluded patients with measured collateral ventilation. Furthermore, different lung function protocols were used in both spirometry as well as body plethysmography. However, patients underwent the same treatment and we were able to include a large number of patients compared to other studies determining MIDs. Furthermore, different volumetric quantification software analysis of the target lobes was performed in the two studies. Recent research suggests that the results from different software programs cannot always be considered interchangeable, however for longitudinal emphysema monitoring it was suggested that the scanning protocol and quantification software needs to be kept constant. 32 In both studies used in our analysis, HRCT was performed following the same scanning protocol and with the same software programs at baseline and 6 months follow-up.
In conclusion, the present study is the first to establish an MID for TLVR measured on HRCT scan in patients with severe emphysema. This value can be useful for both interpreting the results from trials and clinical practice, as well as for designing future studies on lung volume reduction investigating BLVR treatments.
